Literature DB >> 19682336

Thrombin generation in trauma patients.

Nancy M Dunbar1, Wayne L Chandler.   

Abstract

BACKGROUND: Trauma patients are at risk of developing an acute coagulopathy of trauma (ACT) related to tissue injury, shock, and hemodilution. ACT is incompletely understood, but is similar to disseminated intravascular coagulation (DIC) and is associated with poor outcome. STUDY DESIGN AND METHODS: Thrombin generation assays were used to evaluate plasma hemostasis in 42 trauma patients, 25 normal subjects, and 45 patients on warfarin and in laboratory-prepared factor reduced plasma.
RESULTS: Prolonged prothrombin time (PT), more than 18 seconds, or an international normalized ratio of greater than 1.5 was present in 15 trauma patients indicating possible ACT. Native thrombin generation (no activator added, contact activation blocked) showed that Trauma with ACT patients had lag times 68% shorter and peak thrombin generation threefold higher than normal patients indicating the presence of circulating procoagulants capable of initiating coagulation systemically. Trauma patients had lower platelet counts and fibrinogen and Factor (F)II levels putting them at increased risk of bleeding. In laboratory-prepared isolated factor-reduced samples and in patients with vitamin K-dependent factor deficiency due to warfarin, thrombin generation decreased in direct proportion to FII levels. In contrast, in diluted plasma and in trauma patients with reduced factor levels, thrombin generation was increased and associated with slower inhibition of thrombin generation (prolonged termination time) and decreased antithrombin levels (43% of normal in Trauma with ACT).
CONCLUSIONS: Thrombin generation studies indicate that Trauma with ACT patients show dysregulated hemostasis characterized by excessive non-wound-related thrombin generation due to a combination of circulating procoagulants capable of activating coagulation systemically and reduced inhibitor levels allowing systemic thrombin generation to continue once started.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682336     DOI: 10.1111/j.1537-2995.2009.02335.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  51 in total

1.  Quantification of hypercoagulable state after blunt trauma: microparticle and thrombin generation are increased relative to injury severity, while standard markers are not.

Authors:  Myung S Park; Barbara A L Owen; Beth A Ballinger; Michael G Sarr; Henry J Schiller; Scott P Zietlow; Donald H Jenkins; Mark H Ereth; Whyte G Owen; John A Heit
Journal:  Surgery       Date:  2012-02-07       Impact factor: 3.982

2.  Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients.

Authors:  Jessica C Cardenas; Yao-Wei Wang; Jay V Karri; Seenya Vincent; Andrew P Cap; Bryan A Cotton; Charles E Wade
Journal:  Thromb Res       Date:  2020-01-15       Impact factor: 3.944

3.  Platelet dysfunction during trauma involves diverse signaling pathways and an inhibitory activity in patient-derived plasma.

Authors:  Christopher C Verni; Antonio Davila; Steve Balian; Carrie A Sims; Scott L Diamond
Journal:  J Trauma Acute Care Surg       Date:  2019-02       Impact factor: 3.313

4.  [Individualized coagulation therapy: Wish or already reality?].

Authors:  O Grottke
Journal:  Anaesthesist       Date:  2015-10       Impact factor: 1.041

5.  Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI.

Authors:  Samantha J Montague; Céline Delierneux; Christelle Lecut; Nathalie Layios; Robert J Dinsdale; Christine S-M Lee; Natalie S Poulter; Robert K Andrews; Peter Hampson; Christopher M Wearn; Nathalie Maes; Jonathan Bishop; Amy Bamford; Chris Gardiner; Woei Ming Lee; Tariq Iqbal; Naiem Moiemen; Steve P Watson; Cécile Oury; Paul Harrison; Elizabeth E Gardiner
Journal:  Blood Adv       Date:  2018-02-13

6.  Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy.

Authors:  Ross A Davenport; Maria Guerreiro; Daniel Frith; Claire Rourke; Sean Platton; Mitchell Cohen; Rupert Pearse; Chris Thiemermann; Karim Brohi
Journal:  Anesthesiology       Date:  2017-01       Impact factor: 7.892

7.  Characterization of distinct coagulopathic phenotypes in injury: Pathway-specific drivers and implications for individualized treatment.

Authors:  S Ariane Christie; Lucy Z Kornblith; Benjamin M Howard; Amanda S Conroy; Ryan C Kunitake; Mary F Nelson; Carolyn M Hendrickson; Carolyn S Calfee; Rachael A Callcut; Mitchell Jay Cohen
Journal:  J Trauma Acute Care Surg       Date:  2017-06       Impact factor: 3.313

8.  Systemic hyperfibrinolysis after trauma: a pilot study of targeted proteomic analysis of superposed mechanisms in patient plasma.

Authors:  Anirban Banerjee; Christopher C Silliman; Ernest E Moore; Monika Dzieciatkowska; Marguerite Kelher; Angela Sauaia; Kenneth Jones; Michael P Chapman; Eduardo Gonzalez; Hunter B Moore; Angelo D'Alessandro; Erik Peltz; Benjamin E Huebner; Peter Einerson; James Chandler; Arsen Ghasabayan; Kirk Hansen
Journal:  J Trauma Acute Care Surg       Date:  2018-06       Impact factor: 3.313

9.  Thrombin generation and procoagulant microparticle profiles after acute trauma: A prospective cohort study.

Authors:  Myung S Park; Ailing Xue; Grant M Spears; Timothy M Halling; Michael J Ferrara; Melissa M Kuntz; Sabtir K Dhillon; Donald H Jenkins; William S Harmsen; Karla V Ballman; Paul Harrison; John A Heit
Journal:  J Trauma Acute Care Surg       Date:  2015-11       Impact factor: 3.313

10.  Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy.

Authors:  Nena Matijevic; Yao-Wei W Wang; Charles E Wade; John B Holcomb; Bryan A Cotton; Martin A Schreiber; Peter Muskat; Erin E Fox; Deborah J Del Junco; Jessica C Cardenas; Mohammad H Rahbar; Mitchell Jay Cohen
Journal:  Thromb Res       Date:  2014-07-22       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.